Trial Profile
A phase II study of docetaxel and gemcitabine as a second line chemotherapy in cervical cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- Acronyms SCOTSERV
- 30 Jan 2014 Accrual to date is 92% according to United Kingdom Clinical Research Network.
- 07 Apr 2009 Company added as trial sponsor as reported by United Kingdom Clinical Research Network.
- 07 Apr 2009 Planned end date changed from 31 Dec 2007 to 12 Feb 2009 as reported by United Kingdom Clinical Research Network.